MARJORIE CARO: Open Payments
NPI 1902811490 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,237 in 40 payments from 10 companies in 2025. Trend: 2023 $1,009 · 2024 $986 · 2025 $1,237
Food & beverage: $1,127Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $498 |
| Eisai Inc. | 4 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $164 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $88 |
| Neurocrine BioSciences, Inc. | 1 | $34 |
| Biogen, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| TMS NeuroHealth Centers Inc. | 1 | $13 |
Products named: AUSTEDO XR, LEQEMBI, CAPLYTA, JARDIANCE, ABILIFY ASIMTUFII, ABILIFY MAINTENA, REXULTI, INGREZZA.
Industry payments across FL — which companies pay providers there.
